Peri- and post-menopausal women frequently complain of insomnia or poor sleep quality. Sleep disturbance is often attributed to nocturnal hot flashes; however, a sizeable proportion of menopausal women may have a primary sleep disorder. As [...]
Several years ago, we reviewed a paper suggesting that estrogen may have beneficial effects for women with schizophrenia. In this study, women with schizophrenia were treated with estrogen in addition to their antipsychotic medications. [...]
In a study including Latin American women 40 to 59 years of age who had not menstruated for more than 1 year (or had undergone a bilateral oophorectomy), 49.1% of the participants were depressed and [...]
According to a new study, supplementation with calcium and vitamin D does not appear to improve menopause-related vasomotor symptoms, mood changes, or sleep quality in postmenopausal women. This was a secondary analysis of data from the Women’s [...]
The US Food and Drug Administration (FDA) has approved a novel estrogen-based drug for women for the treatment of moderate-to-severe vasomotor symptoms and osteoporosis associated with menopause. Duavee (Wyeth Pharmaceuticals) is a once-a-day tablet containing a combination of conjugated estrogens and bazedoxifene, an estrogen agonist/antagonist.
Several recent studies have examined the impact of various types of physical activity on menopausal symptoms, including hot flashes, night sweats, and sleep disturbance.
In a recent randomized, single-blind, controlled, clinical trial, 187 postmenopausal women reporting at least 7 hot flashes per day received five weekly sessions of either clinical hypnosis or structured-attention control. Hot flash score were assessed by daily diaries on weeks 2 to 6 and at week 12.
We previously reported on studies suggesting estrogen may be helpful for the treatment of depression in peri- and post-menopausal women, either alone or in combination with an antidepressant. In addition, other studies have suggested that older, postmenopausal women may respond more poorly to antidepressants than premenopausal women. Two recent studies attempt to better understand the impact of reproductive hormones on clinical presentation and treatment response of depression in women.
Soy-based products have long been touted as a treatment for menopausal symptoms. However, many of the clinical studies measuring the effectiveness of dietary sources of soy isoflavones (e.g., soy beverages, soy powder) for the treatment of menopausal vasomotor symptoms (i.e., hot flushes, night sweats) have been negative. Less is known about the effects of soy on cognition. A large clinical trial suggests that soy may not have any positive effects on cognition in postmenopausal women.
As a result of dramatically increased life expectancies in industrialized countries, healthy women today expect to spend nearly 40% of their lives after menopause. For these postmenopausal women, lack of estrogen may contribute to long-term adverse effects, including cardiovascular disease and osteoporosis. Many postmenopausal women might benefit from hormone replacement therapy (HRT) with estrogens and progestins; however, a number of recent studies in the USA and Europe suggest that the potential risks of hormonal replacement therapy may sometime exceed the expected benefits. Thus, many treaters now avoid the use of hormone replacement therapy in peri- and postmenopausal women.